Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320108 | 1.00 | KDM4E (0.33) | KDM4EESR1KMT2ASMN1; SMN2XPO1 | |
| SCHEMBL1580172 | 0.81 | KDM4E (0.42) | KDM4EESR1SMN1; SMN2LMNAHDAC3 | |
| SCHEMBL1580175 | 0.81 | KDM4E (0.42) | KDM4EESR1SMN1; SMN2LMNAHDAC3 | |
| SCHEMBL18706679 | 0.79 | LMNA (0.37) | KDM4EESR1SMN1; SMN2XPO1LMNA | |
| SCHEMBL18706675 | 0.79 | LMNA (0.37) | KDM4EESR1SMN1; SMN2XPO1LMNA | |
| SCHEMBL16642332 | 0.77 | ALDH1A1 (0.38) | KDM4EESR1SMN1; SMN2XPO1LMNA | |
| SCHEMBL30288729 | 0.77 | ALDH1A1 (0.38) | KDM4EESR1SMN1; SMN2XPO1LMNA | |
| SCHEMBL15278593 | 0.77 | XPO1 (0.34) | KDM4EESR1KMT2ASMN1; SMN2XPO1 | |
| SCHEMBL19900075 | 0.77 | ALDH1A1 (0.38) | KDM4EESR1SMN1; SMN2XPO1LMNA | |
| SCHEMBL732497 | 0.77 | TRPA1 (0.43) | KDM4EKMT2ASMN1; SMN2XPO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814850-B9 | NEW HISTONE DEACETYLASES INHIBITORS | DAC SRL (IT) | 2015-02-25 | — | — | EP | disclosed |
| EP-1814850-B1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC SRL (IT) | 2013-07-03 | — | — | EP | disclosed |
| US-8242175-B2 | Class of histone deacetylase inhibitors | DAC S.R.L. (IT) | 2012-08-14 | — | — | US | disclosed |
| US-8058273-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2011-11-15 | — | — | US | disclosed |
| US-20110077247-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.I. (IT) | 2011-03-31 | — | — | US | disclosed |
| US-7803800-B2 | Histone deacetylases inhibitors | DAC S.R.L. (IT) | 2010-09-28 | — | — | US | disclosed |
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | DAC S.R.L. (IT) | 2010-09-23 | — | — | US | disclosed |
| EP-2049508-B1 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC SRL (IT) | 2010-06-09 | — | — | EP | disclosed |
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-05-06 | — | — | US | disclosed |
| EP-2049508-A2 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.r.l. (IT) | 2009-04-22 | — | — | EP | disclosed |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | GENEXTRA S.P.A. (IT) | 2008-04-24 | — | — | US | disclosed |
| WO-2007113249-A2 | N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077247-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC11 | KDM4E 259/4885ESR1 1469/4885KMT2A 154/4885 |
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC11 | KDM4E 259/4885ESR1 1469/4885KMT2A 154/4885 |
| US-20100240660-A1 | NEW HISTONE DEACETYLASES INHIBITORS | HDAC1, HDAC3, HDAC11 | KDM4E 170/4885ESR1 3961/4885KMT2A 51/4885 |
| US-20080096889-A1 | Histone Deacetylases Inhibitors | HDAC1, HDAC3, HDAC11 | KDM4E 163/4885ESR1 3824/4885KMT2A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.